Positron emission tomography-based molecular imaging biomarkers may predict therapeutic response and survival in patients with metastatic castration-resistant prostate cancer, researchers say. READ MORE

Research in Review

Patients choosing surveillance over aggressive treatment for prostate cancer are not being monitored as closely as they should be, according to a new study published by a team of University of California, Los Angeles (UCLA) researchers in the journal Cancer.